LncRNA OR2A1-AS1 指数预测生发中心样弥漫性大 B 细胞淋巴瘤的生存。
LncRNA OR2A1-AS1 index predicts survival in germinal center-like diffuse large B-cell lymphoma.
机构信息
Department of Hematology, The First People's Hospital of Wenling, Wenling, China.
Department of Pathology, The First People's Hospital of Wenling, Wenling, China.
出版信息
J Clin Lab Anal. 2022 Oct;36(10):e24680. doi: 10.1002/jcla.24680. Epub 2022 Sep 4.
BACKGROUND
Diffuse large B-cell lymphoma (DLBCL) is a highly aggressive form of non-Hodgkin lymphoma. Long noncoding RNA (lncRNA) has been evaluated as prognostic markers in various carcinomas. However, the prognostic value of the lncRNA index in DLBCL has not been fully understood. Hence, this study aimed to identify the prognostic value of lncRNA olfactory receptor family 2 subfamily A member 1-antisense RNA 1 (OR2A1-AS1) in DLBCL.
METHODS
The Gene Expression Omnibus (GEO) database was used to obtain the GSE97336 dataset comprising lncRNA expression profiles. Quantitative reverse transcription polymerase chain reaction (QRT-PCR) was conducted to evaluate the expression of OR2A1-AS1 in 98 cases of DLBCL.
RESULTS
OR2A1-AS1 expression was considerably reduced in DLBCL patients, reduced OR2A1-AS1 expression was linked to a shorter overall survival (OS) and progression-free survival (PFS) in DLBCL patients, especially those with the germinal center B-cell-like subtype (GCB). Multivariate analysis (MVA) revealed that the OR2A1-AS1 index had prognostic significance. Patients with low OR2A1-AS1 expression have a poor prognosis.
CONCLUSIONS
OR2A1-AS may represent an effective predictor of patients' outcomes with DLBCL.
背景
弥漫性大 B 细胞淋巴瘤（DLBCL）是一种高度侵袭性的非霍奇金淋巴瘤。长链非编码 RNA（lncRNA）已被评估为各种癌的预后标志物。然而，lncRNA 指数在 DLBCL 中的预后价值尚未完全理解。因此，本研究旨在确定嗅觉受体家族 2 亚家族 A 成员 1-反义 RNA 1（OR2A1-AS1）在 DLBCL 中的预后价值。
方法
使用基因表达综合数据库（GEO）获取包含 lncRNA 表达谱的 GSE97336 数据集。采用定量逆转录聚合酶链反应（QRT-PCR）检测 98 例 DLBCL 患者的 OR2A1-AS1 表达。
结果
OR2A1-AS1 在 DLBCL 患者中表达显著降低，OR2A1-AS1 表达降低与 DLBCL 患者总生存期（OS）和无进展生存期（PFS）缩短相关，尤其是生发中心 B 细胞样亚型（GCB）患者。多变量分析（MVA）显示 OR2A1-AS1 指数具有预后意义。OR2A1-AS1 低表达的患者预后不良。
结论
OR2A1-AS 可能是 DLBCL 患者预后的有效预测指标。
Zotero 插件